SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Pastimes : Investment Chat Board Lawsuits

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jeffrey S. Mitchell who wrote (564)11/25/2000 3:42:04 AM
From: Jeffrey S. Mitchell  Read Replies (2) of 12465
 
Re: 11/15/00 - [STGI] Court Grants STGI Summary Judgment

Court Grants STGI Summary Judgment

LAS VEGAS, Nov 15, 2000 (BW HealthWire) -- Steroidogenesis Inhibitors International Inc. (OTCBB: STGI chart, msgs) has won a Summary Judgment.

On Monday, October 30, 2000, the Honorable Nancy Saitta heard arguments on a Motion for Summary Judgment filed by STGI as against its former officer Alfred T. Sapse, in relationship to a defamation case that Sapse had filed against STGI. After extensive arguments on the issues the Court granted Summary Judgment in favor of STGI on all issues. Sapse's complaint centered on an August 4th press release issued by STGI. In making her ruling, Judge Saitta determined that all the statements contained within the press release were constitutionally protected speech relating to the author's opinion. Additionally, the Court ruled that Sapse had completely failed to show any damages despite the claims in his complaint. As a result, Sapse's complaint has been dismissed.

About STGI

Steroidogenesis Inhibitors International, Inc., is a pioneering biopharmaceutical scientific incubator focused on developing therapeutic drugs primarily for the treatment of high cortisol related diseases. The Company's lead proprietary drug Anticort(TM) is the subject of FDA Phase1B/2A clinical trial for indications in HIV. The Company is also exploring the efficacy of Anticort(TM) as an effective treatment for other high cortisol related diseases such as Alzheimer's, Parkinson's, and Cancer.

For more information please call Shayne Payne or Dian Griesel, Ph.D. at The Investor Relations Group, Inc. 212-736-2650 or visit www.anticort.com

This release contains statements about the future that could differ from actual results. The Statements are subject to risk and uncertainties, including but not limited to, the impact of competition, fluctuations in stock price and liquidity, fluctuating operating results and other risks as detailed in the Company's filings with the SEC.
Contact:

The Investor Relations Group, Inc., New York
Shayne Payne or Dian Griesel
212/736-2650
www.anticort.com


siliconinvestor.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext